Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/203—Retinoic acids ; Salts thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4858—Organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/513—Organic macromolecular compounds; Dendrimers
  • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
  • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

• Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson' s disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma.
• neuro-degenerative diseases such as Hutchinson Disease, Parkinson' s disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes
• cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma.
• Neurodegenerative diseases such as Alzheimer's disease, Hutchinson's Disease, Parkinson's disease, Kuru, Creutzfeldt - Jakob disease and other spongiform encephalopathies remain major health problems. With respect to Alzheimer's, Hutchinson's and Parkinson's diseases, these diseases tend to manifest themselves in older individuals and as the diseases progress; the afflicted individuals are less able to care for themselves.
• cancers such as, by way of example, without limitation, prostate cancer, Bryostatin 1 inhibits phorbol ester- induced apoptosis in prostate cancer cells by differentially modulating protein kinase C (PKC) delta translocation and preventing PKCdelta-mediated release of tumor necrosis factor-alpha.
• PKC protein kinase C
• virus latency diseases such as HIV latency, Bryostatin-1 , as well as many PKC agonists, activates cellular transcription factors such as NF-kB that binds the HIV-1 promoter and regulates its transcriptional activity.
• HIV-1 latency the viral promoter is less accessible to cellular transcription factors because nuclear histones surrounding the viral promoter are deacetylated (compacted chromatin).
• HDAC inhibitors may increase the aceytation of histones (relaxed chromatin) and then transcription factors may have an easy access to the HIV promoter.
• opthalmic disease such as by way of example, without limitation, glaucoma, the presence of beta amyloid is associated with elevated intra ocular pressure. Currently there are very limited means to treat these diseases.
• Embodiments of the present invention are directed to single and combination therapies, drug delivery systems, dosage forms and methods for the treatment of neurodegenerative diseases, cancers, viral latencies and optical diseases.
• the neurodegenerative diseases which are the object of treatment in the present invention are exemplified by Alzheimer's disease, Hutchinson's Disease, Parkinson's disease, Kuru, Creutzfeldt - Jakob disease, Down's syndrome and spongiform encephalopathies.
• Other diseases include cancers such as prostate cancer and viral latencies such as HIV and herpes.
• the embodiments directed to an article of manufacture comprise a dosage form comprising an effective amount of a byostatin or Bryoid with an effective amount of a Retinoid.
• drug form refers to a means for administering a drug, such as by way of example, without limitation, capsules, tablets, pills, films ,ointments, creams, solutions, suspensions, aerosals, pastes, drops, suppositories, powders for reconstitution, injectables, intravenous solutions and the like.
• a bryostatin refers to any and all bryostatins and derivatives thereof. Twenty bryostatins have been identified and certain examples feature a bryostatin that is bryostatin- 1.
• Embodiments of the present invention feature a first Bryoid composition having a molecular weight of approximately 896 - 898 Amu (Mass + Sodium) having a purity of approximately 50 % to a crystal forming purity.
• the first Bryoid composition can also be characterized as a Bryoid compound having a molecular weight of approximately 873-875 Amu (monoisotopic mass) having a purity of approximately 50% and a crystal forming purity.
• the first Bryoid composition has a measured mass plus sodium of 897.2 Amu and a measured monoisotopic mass of 874.2 Amu.
• BIO The detailed discussion which follows will refer to this Bryoid as BIO.
• Embodiments of the present invention feature a second Bryoid composition having a molecular weight of approximately 910 - 912 Amu (Mass + Sodium) having a purity of approximately 50 % to a crystal forming purity.
• the second Bryoid composition can also be characterized as a Bryoid compound having a molecular weight of approximately 888-890 Amu (monoisotopic mass) having a purity of approximately 50% and a crystal forming purity.
• the second Bryoid composition has a measured mass plus sodium of 911.5 Amu and a measured monoisotopic mass of 888.9 Amu.
• Embodiments of the present invention feature a third Bryoid composition having a molecular weight of approximately 868 - 870 Amu (Mass + Sodium) having a purity of approximately 50 % to a crystal forming purity.
• the third Bryoid composition can also be characterized as a Bryoid compound having a molecular weight of approximately 846 - 848 Amu (monoisotopic mass) having a purity of approximately 50% and a crystal forming purity.
• the third Bryoid composition has a measured mass plus sodium of 869.5 Amu and a measured monoisotopic mass of 846.6 Amu. The detailed discussion which follows will refer to this Bryoid as B 14B.
• Embodiments of the present invention feature a fourth Bryoid composition having a molecular weight of approximately 895 - 897 Amu (Mass + Sodium) having a purity of approximately 50 % to a crystal forming purity.
• the fourth Bryoid composition can also be characterized as a Bryoid compound having a molecular weight of approximately 872 - 874 Amu (monoisotopic mass) having a purity of approximately 50% and a crystal forming purity.
• the fourth Bryoid composition has a measured mass plus sodium of 895.5 Amu and a measured monoisotopic mass of 872.6 Amu. The detailed discussion which follows will refer to this Bryoid as B14C.
• crystal forming purity means the composition has a purity which enables the composition to form crystals. Normally, such purity is greater than 90%, and more often greater than 95% purity. Examples presented in this application feature compositions having a purity greater than 99%. Crystal purity would comprise compositions in which no impurities can be detected, but is not so limited.
• the first Bryoid, second Bryoid, third Bryoid, and fourth Bryoid described above are the subject of a co-pending patent application of the present inventor and applicant filed November 27, 2012, serial number US 61/730,227. The entire contents of the co-pending application are incorporated by reference.
• Embodiments of the present invention feature a Bryoid present in an amount to stimulate the production of alpha secretase.
• a Bryoid is present for administration in a dose of 0.1 - 50 micrograms per square meter of surface area per week.
• Another embodiment of the present invention features a Bryoid present for administration in a dose of 5- 10 micrograms per square meter of surface area per week.
• FIG. 1 For example, without limitation, the retinoid is present in a dose of 1.0 - 240 mg per day.
• Embodiments of the present invention feature nanospheres comprising a biopolymer which is resistant to acid.
• one biopolymer is a poly (D, L-lactide- coglycoside).
• This biopolymer has two components.
• Embodiments of the present invention feature a poly (D, L-lactide-co-glycoside) having a ratio of lactide and glycoside of 25-75 % lactide with the remaining comprising glycoside. A common ratio is 50:50 lactide to glycoside as determined by weight.
• This biopolymer is resistant to gastric acid degradation and allows oral delivery of the drug to the small intestine for absorption.
• Nanospheres are about 1 to 1000 nanometers in diameter.
• Embodiments of the present invention feature spheres that are lyophilized for reconstitution in an aqueous solution.
• Another embodiment features spheres held in suspension for oral administration and/or held in an oral dosage form selected from the group of tablets, capsules, gel caps, and powders. Suspensions for oral administration are preferably flavored to improve patient acceptance.
• a further embodiment of the present invention is directed to a method of treating neurodegenerative disease.
• the method comprises the steps of administering an effective amount of a bryostatin held in a plurality of spheres, each sphere comprising a biopolymer and bryostatin, and each sphere having a diameter of one to 1000 nanometers.
• Embodiments of the present method feature a bryostatin selected from the group consisting of Bryostatins 1-20. Certain examples feature a bryostatin that is bryostatin- 1. Several bryostatins of great potency are bryostatin-3; and the first Bryoid, second Bryoid and third bryoid referenced above.
• Embodiments of the present invention feature bryostatin administered in an amount to stimulate the production of alpha secretase.
• bryostatin is administered in a dose of 0.1 - 50 micrograms per square meter of surface area per week.
• Another embodiment of the present invention features a bryostatin administered in a dose of 5- 10 micrograms per square meter of surface area per week.
• retinoid is bioavailable in an oral form and selected from the group comprising retinoic acid, retinol, retinol acetate, retinol palmitate, 13-cis-retinoic acid, and bexarotene.
• the Examples will feature the retinoid, retinoic acid.
• the Examples feature the retinoid in an amount to increase expression of alpha secretase.
• the retinoid is administered in a dose of 1.0 - 240 mg per day.
• One embodiment of the present invention features a biopolymer which is resistant to acid.
• one acid resistant biopolymer is a poly (D, L-lactide- coglycoside).
• Poly (D, L-lactide-co-glycoside) has a ratio of lactide and glycoside. A preferred ratio is 25-75 % lactide with the remaining comprising glycoside.
• the microspheres are lyophilized for reconstitution in an aqueous solution, or held in suspension for oral administration or held in an oral dosage form selected from the group of tablets, capsules, gel caps, and powders.
• embodiments of the present invention feature an effective amount of a bryostatin dissolved in pharmaceutically acceptable oil for oral administration for the treatment of neuro-degenerative disease.
• the term "pharmaceutically acceptable oil” refers to oils which are reasonably well tolerated for oral ingestion in small amounts of 5 to 10 milliliters.
• Embodiments of the present invention feature olive oil.
• Other embodiments comprise, by way of example, without limitation include, cotton seed oil, cod liver oil, castor oil, safflower oil, peanut oil, sesame oil, corn oil, vegetable oils, oils originating with animals, and other oils commonly used in the food industry.
• the oil is preferably administered in a gel cap.
• An effective amount of Bryostatin for humans is about 0.1 to 3.0 mg per day in the pharmaceutically acceptable oil and approximately 100 micrograms to 2 mg per day as in the microsphere.
• the article of manufacture comprise a retinoid dissolved in pharmaceutically acceptable oil for oral administration for the treatment of neurodegenerative disease, cancer and viral latencies.
• the pharmaceutically acceptable oil has the retinoid bioavailable in an oral form and selected from the group comprising retinoic acid, retinol, retinol acetate, retinol palmitate, 13-cis-retinoic acid, and bexarotene.
• the Examples will feature the retinoid, retinoic acid.
• the Examples feature the retinoid in an amount to increase expression of alpha secretase.
• the retinoid is present in a dose of 1.0 - 240 mg per day.
• inventions of the article of manufacture comprise a bryostatin and retinoid dissolved in pharmaceutically acceptable oil for oral administration for the treatment of neuro-degenerative disease, cancer, viral latencies and optical diseases.
• a further embodiment of the present invention is directed to a method of treating neurodegenerative disease, cancer, viral latency and/or optical diseases comprising the steps of administering orally an effective amount of a bryostatin dissolved in pharmaceutically acceptable oil.
• embodiments of the present invention feature dosage forms and methods for the oral administration of an effective amount of a bryostatin with and without a retinoid.
• Figure 1 depicts a microsphere embodying features of the present invention
• Figure 2 depicts an apparatus for making one or more microspheres of the present invention
• Figure 3 shows that Bryostatin-1 induced sAPP-a formation in SH-SY5Y neuroblastoma cells is increased at 3h by 2 ⁇ and 4 ⁇ retinoic acid.
• Retinoic acid an inducer of ADAMlO/alpha-secretase increased the generation of sAPP-a by SH-SY5Y cells.
• Left panel shows 6E10 western blots for sAPP-a,
• Right panel shows densitometric analysis.
• *-p ⁇ 0.05 vs control, **-p ⁇ 0.01 vs control, n 3; and
• Figure 4 depicts the effect of retinoic acid (RA, 2 ⁇ ) and Bryostatin-1 on the level of sAPPa in SH-SY5Y cells.
• Cells were treated with RA, Bryostatin-1 (10 "9 M) + RA, Bryostatin-1 (10 "10 M), RA+Bryostatin-1 (10 "10 M) for 3h.
• Representative western blots show sAPPa recovered from culture medium. Both Bryostatin-1 and RA significantly increased sAPPa compared to control (p ⁇ 0.05, p ⁇ 0.01). Combining RA and Bryostatin-1 significantly increased sAPPoc recovered from culture medium.
• Embodiments of the present invention will be described with respect to single and combination therapy, drug delivery system, dosage form and method for the treatment of neuro-degenerative diseases exemplified by Alzheimer's disease, with the understanding that the discussion relates to other neuro-degenerative diseases as well, cancers such as prostate cancer and viral latencies such as HIV and herpes.
• This discussion will feature the preferred embodiments of the invention with the understanding that features of the invention are capable of modification and alteration without departing from the teaching.
• microsphere 11 generally designated by the numeral 11 embodying features of the present invention is depicted.
• the microsphere 11 when combined with an adequate number of like microspheres comprises an effective dose of a bryostatin in a biopolymer.
• Each microsphere 11 has a diameter of one to 1000 nanometers.
• the article of manufacture may have an irregular shape, roughness, or be filamentous in form.
• a bryostatin refers to any and all bryostatins and Bryoids and derivatives thereof. Bryostatins and Bryoids are isolated in accordance with Castor, U.S Patent 5,750,709 and Castor "Supercritical fluid Isolation of Bryostatin- 1 , Phase II Final Report, SBIR Grant No. 5 R44 CA64017-03, April 21 2001.
• bryostatin- 1 is well characterized in the art and the structure of such compound need not be reproduced here.
• bryostatins of high potency are bryostatin-3 and first bryostatin, second bryostatin and third bryostatin referenced previously and the subject of the co-pending patent application incorporated by reference.
• the bryostatin is administered in an amount to stimulate the production of alpha secretase.
• bryostatin is administered in a dose of 0.1 - 50 micrograms per square meter of surface area per week.
• Another embodiment of the present invention features a bryostatin administered in a dose of 5- 10 micrograms per square meter of surface area per week.
• the retinoid is present in the same biopolymer, or made separately and combined prior to administration, or administered at the same time or close in time to have a combined effect with the bryostatin.
• the retinoid is bioavailable in an oral form and selected from the group comprising retinoic acid, retinol, retinol acetate, retinol palmitate, 13-cis-retinoic acid, and bexarotene.
• Retinoic acid is available as an orally administered drug and is sold under the pharmaceutical name Tretinoin and tradename Retin -A®.
• Tretinoin and tradename Retin -A® it is believed that the retinoid acts synergistically with the bryostatin to increase expression of alpha secretase.
• the retinoid is administered in a dose of 1.0 - 240 mg per day.
• Embodiments of the present invention feature a biopolymer resistant to acid.
• resistance to acid refers to stomach acid at a pH of approximately 1 to 3 for a period of time of about 0.5 to 4.0 hours.
• One biopolymer is a poly (D, L-lactide- coglycoside). This biopolymer has two components, a lactide and a glycoside component.
• Embodiments of the present invention feature a poly (D, L-lactide-co-glycoside) having a ratio of lactide and glycoside of 25-75 % lactide with the remaining comprising glycoside. A common ratio is 50:50 lactide to glycoside as determined by weight.
• This biopolymer is resistant to acid degradation and allows oral delivery of the drug to the small intestine for absorption.
• Embodiments of the present invention feature microspheres that are lyophilized for reconstitution in an aqueous solution.
• Another embodiment features microspheres held in suspension for oral administration and/or held in an oral dosage form selected from the group of tablets, capsules, gel caps, and powders. Methods of making tablets, capsules, gel caps and powders are well known in the art. (Remington, 'The Science and Practice of Pharmacy'- 20 th Edition Lippincott, Williams and Williams). Suspensions for oral administration are preferably flavored to improve patient acceptance.
• Another embodiment of the present invention features pharmaceutically orally acceptable oil containing an effective amount of bryostatin. An amount of oil for administration is determined, and an effective amount of bryostatin is dissolved in such oil in a manner known in the art. Preferably, the amount of oil which is intended for oral administration is enclosed in a gel cap in a manner known in the art. For example, Vitamin D and Vitamin E supplements are often enclosed in gel cap formulations.
• the present method and apparatus will be described with respect to Figure 2 which depicts in schematic form a polymer sphere apparatus, generally designated by the numeral 13.
• the polymer sphere apparatus is comprised of the following major elements: a polymer vessel 15, a Bryostatin drug injection assembly 17, an admixture chamber 19, a depressurization vessel 21, and an orifice nozzle 23.
• Polymer vessel 15 is in fluid communication with a supercritical critical or near critical syringe pump 25 via conduits 27a, 27b and 27c.
• Supercritical, critical or near critical pump 25 is in fluid communication with a source of supercritical, critical or near critical fluid.
• Polymer vessel 15 is also in fluid communication with a modifier syringe pump 31 via conduit 33 which intersects with conduit 27a at junction 35.
• Modifier syringe pump 31 is in communication with a source of modifiers and/or entrainers (not shown).
• Polymer vessel 15 is loaded with polymer. This polymer vessel receives supercritical, critical or near critical fluid from supercritical critical or near critical pump 25 via conduits 27a, 27b and 27c. Polymer vessel 15 receives modifiers and/or entrainers from modifier pump 31 via conduit 33. Polymer is dissolved in the supercritical, critical or near critical fluid and modifier to form a polymer solution. Formation of the polymer solution is facilitated by circulating the polymers and supercritical, critical or near critical fluid in a loop with a conduits 27d, 27d, 27 e, 27 f, and 27g, a master valve 29, a static mixer 31, and a circulation pump 33.
• Polymer vessel 15 is in fluid communication with admixture chamber 19 via conduits 37 and 39.
• Admixture chamber 19 is also in fluid communication with bryostatin drug injection assembly 17.
• Bryostatin drug injection assembly 17 comprises bryostatin drug syringe pump 43, a source of a bryostatin 41 and conduit 45.
• Bryostatin drug syringe pump 43 is in communication with a source of bryostatin material and pressurizes and compels such material through conduit 45.
• Conduit 45 is in communication with admixture chamber via conduits 39 which intersects conduit 45 at junction 47.
• junction 47 is a mixing
• Admixture vessel 19 is in the nature of an inline mixer and thoroughly mixes incoming streams from the polymer vessel 15 and bryostatin drug injection assembly 17.
• Admixture vessel 19 is in communication with orifice nozzle 23 via conduit 49.
• Orifice nozzle 23 is in the nature of a back pressure regulator and has a nozzle defining one or more orifices which discharge into depressurization vessel 21 via conduit 51.
• orifice nozzle 23 controls pressure and decompression rates such that a supercritical critical or near critical carbon dioxide enters the orifice at a rate of about 0.425 mls/min and 0.075 mls/min acetone or about 0.5 mls/min carbon dioxide and ethanol combined to maintain system pressure at 2,500 psig.
• the operating pressure of the system can be preset at a precise level via a computerized controller (not shown) that is part of the syringe pumps. Temperature control in the system is achieved by enclosing the apparatus 11 in 1/4" Lexan sheet while utilizing a Neslab heating/cooling system coupled with a heat exchanger (not shown) to maintain uniform temperature throughout the system.
• polymeric materials are first packed into the polymer vessel 15.
• Supercritical critical or near critical fluid and an ethanolic solution of one or more bryostatin compounds are charged into the supercritical, critical or near critical syringe pumps 25 and 31, respectively, and brought to the desired operating pressure.
• an ethanol solution of one or more bryostatin compounds is charged into bioactive syringe pump 43.
• the dynamic operating mode for all pumps is set so that each pump can be operated at its own desired flow rate.
• the supercritical critical or near critical stream flows through the polymer vessel 15, dissolves polymer and contacts the one or more bryostatin compounds, or one or more bryostatin and retinoid compounds, stream at junction 47.
• the mixture of supercritical critical nears critical fluid, bryostatin drug, or bryostatin and retinoid, or retinoid alone and polymer materials is then passed through admixture chamber 19 for further mixing.
• the mixed solution enters orifice nozzle 23 and is injected into a 10% sucrose solution containing 0.1 % polyvinyl alcohol, 40 % ethanol with trace acetic acid in the depressurization vessel 21.
• polymer spheres containing one or more bryostatin compounds, or polymer spheres containing one or more bryostatin and retinoid compounds, or polymer compounds containing retinoid compounds are formed in the 10% sucrose solution, 0.1 % polyvinyl alcohol, 40 % ethanol with trace acetic acid.
• the expanded supercritical fluid exits the system via a vent line on the depressurization vessel 21.
• the polymer nanospheres are in the nature of microspheres 11. These microspheres 11 are frozen at -80° degrees Centigrade and lyophilized.
• Retinoic acid enhances Bryostatin-1 mediated alpha secretase activity.
• Figure 3 shows that Bryostatin-1 induced sAPP-a formation in SH-SY5Y neuroblastoma cells is increased at 3h by 2 ⁇ and 4 ⁇ retinoic acid.
• Retinoic acid, an inducer of ADAM 10/alpha- secretase increased the generation of sAPP-a by SH-SY5Y cells.
• Figure 2 shows that in SH-SY5Y neuroblastoma cells, sAPP formation is increased by 2 ⁇ retinoic acid (p ⁇ 0.01) similar to 10 ⁇ 9 M Bryostatin-1. An additive effect was observed when retinoic acid (RA) was added at 2 ⁇ concentration with Bryostatin-1 at 10 "9 M and 10 " 10 M.
• retinoic acid RA
• FIG. 2 shows that both RA and Bryostatin-1 can each significantly increase expression of ADAMIO (the major form of a-secretase) and that in combination there is at least an additive effect on expression.
• ADAMIO the major form of a-secretase
• Bryostatin-1 increases the expression of -secretase, which is a novel and unanticipated effect of Bryostatin-1. Therefore, Bryostatin-1 may increase -secretase processing through 2 independent mechanisms: (i) activation of PKCs which stimulate secretase; and (ii) increased expression of -secretase.
• ADAMIO ADAMIO mRNA synthesis may be increased by Bryostatin-1 ultimately leading to greater a-secretase.
• Oil based bryostatin solutions are made with the desired amount of bryostatin dissolved in olive oil with vitamin E as a preservative and lecithin and medium chain triglyceride emulsifiers to increase bioavailability.
• the oil with the dissolved bryostatin is encapsulated in gel capsules with a nitrogen purge and head.
• the oil with dissolved bryostatin is administered as a liquid dosage form.
• the oil with dissolved bryostatin may also be emulsified and administered as a liquid formulation. Emulsification may mask some of the less desirable taste and texture associated with oil based oral formulations.
• Oil based bryostatin and retinoic acid solutions are made with the desired amount of bryostatin and retinoic acid dissolved in olive oil with vitamin E as a preservative and lecithin and medium chain triglyceride emulsifiers to increase bioavailability.
• the oil with the dissolved bryostatin and retinoic acid is encapsulated in gel capsules with a nitrogen purge and head.
• the oil with dissolved bryostatin and retinoic acid is administered as a liquid dosage form.
• the oil with dissolved bryostatin and retinoic acid may also be emulsified and administered as a liquid formulation. Emulsification may mask some of the less desirable taste and texture associated with oil based oral formulations.
• Microspheres comprising polymers and bryostatin 1 were prepared in accordance with the methods described above. The results are summarized in Table 1 below.
• the nanospheres appear stable at 4-25°C (Centigrade) for at least one week duration. Further, the nanospheres appear stable in solutions at about pH 1.13 at 37°C (Centigrade), similar to a stomach environment.
• Microspheres comprising polymers and one or more bryostatin and retinoid compounds are prepared in accordance with the methods described above. Water Maze Studies
• mice that received bryostatin- 1 at a dose of 5 micrograms/mouse on alternative days orally in an oil formulation showed significant protection against Alzheimer's disease mediated memory loss produced by the APP/PS1 mutations as compared with memory acquisition skills seen in control animals.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biomedical Technology (AREA)
• Virology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Physics & Mathematics (AREA)
• Zoology (AREA)
• Botany (AREA)
• Optics & Photonics (AREA)
• Nanotechnology (AREA)
• Molecular Biology (AREA)
• Psychology (AREA)
• Psychiatry (AREA)
• Biotechnology (AREA)
• Hospice & Palliative Care (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Ophthalmology & Optometry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=50828429

Family Applications (1)

Country Status (6)

Families Citing this family (4)

Citations (5)

Family Cites Families (31)

• 2013
  • 2013-11-26 JP JP2015545197A patent/JP6579956B2/ja not_active Expired - Fee Related
  • 2013-11-26 US US14/646,817 patent/US10828276B2/en active Active
  • 2013-11-26 EP EP13858873.6A patent/EP2925314B1/en active Active
  • 2013-11-26 CN CN201380070968.5A patent/CN105228614A/zh active Pending
  • 2013-11-26 HK HK16106972.1A patent/HK1218882A1/zh unknown
  • 2013-11-26 WO PCT/US2013/072076 patent/WO2014085494A1/en not_active Ceased

Patent Citations (5)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events